Shionogi Initiated P-I/II/III Clinical Trial (Part 2) and P-III Additional Dose Clinical Trial of S-268019 for COVID-19
Shots:
- The company initiated a P-I/II/III trial (part2) consisting of the primary & booster vaccination part & also initiates P-III additional dose trial evaluating S-268019 in Japanese pediatric patients
- In the primary vaccination part, children aged ≥20yrs. will be used to compare the immunogenicity following a primary series of S-268019 to children in the P-III trial. In the booster vaccination part, comparing the immunogenicity following 3rd dose of S-268019 to the initial series of S-268019
- In the additional dose trial, the immunogenicity of an additional dose of S-268019 or Comirnaty in pediatric patients aged 5-11yr., ≥5mos. after receiving a primary series of Comirnaty will be compared to patients aged ≥20yr., ≥6mos. S-268019 is under the PMDA’s review
Ref: Shionogi | Image: Shionogi
Related News:- Shionogi Seeks Japan Approval of S-268019 for the Treatment of COVID-19
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
